Hoth Therapeutics adds $4.82M to ATM; $5.5M sold to date
Hoth Therapeutics amended its prospectus supplement to expand its at-the-market program with H.C.
Rhea-AI Filing Summary
Hoth Therapeutics amended its prospectus supplement to expand its at-the-market program with H.C. Wainwright. The company is now offering up to $4,821,200 of common stock under the existing ATM agreement, after effectiveness and pursuant to General Instruction I.B.6 of Form S-3.
Since launching the ATM, Hoth has sold 3,919,559 shares for gross proceeds of about $5.5 million. The company cites a public float of approximately $30,968,682, which caps primary offerings at one-third of float over any 12-month period; the new $4,821,200 capacity reflects that limit. Shares trade on Nasdaq as “HOTH,” with a last reported sale price of $1.28 on November 12, 2025.
Positive
- None.
Negative
- None.
Insights
HOTH ups ATM capacity by $4,821,200 under S-3 I.B.6 limits.
Hoth is increasing its at-the-market (ATM) headroom to sell up to $4,821,200 of common stock via H.C. Wainwright. This follows prior ATM sales of 3,919,559 shares for roughly $5.5 million, indicating ongoing use of the program for working capital at prevailing market prices.
The filing anchors eligibility to a public float of about $30,968,682, which constrains primary issuance to one-third of float in any 12 months. The disclosed headroom aligns with that cap and indicates compliance with General Instruction I.B.6.
Execution will depend on trading volumes and price levels achieved in ordinary market transactions. Subsequent filings may provide updates on actual shares sold and proceeds realized.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is HOTH (HOTH) offering in this amendment?
How much has HOTH already sold through the ATM?
Why is the new ATM capacity set at $4,821,200?
Who is the sales agent for HOTH’s ATM program?
Where is HOTH listed and what was the recent price?
Does HOTH receive proceeds from the ATM sales?
AI-generated analysis. How Rhea-AI works. Not financial advice.
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-272620
AMENDMENT NO. 2 DATED NOVEMBER 13, 2025
TO PROSPECTUS SUPPLEMENT DATED NOVEMBER 8, 2024
TO PROSPECTUS DATED JUNE 16, 2023
Up to $4,821,200
Common Stock
Hoth Therapeutics, Inc.
This Amendment No. 2 to prospectus supplement (“Amendment”) amends and supplements the information in the prospectus, dated June 16, 2023, filed as a part of our registration statement on Form S-3 (File No. 333-272620), as supplemented by our prospectus supplement dated November 8, 2024 as amended by Amendment No. 1 dated February 7, 2025 (collectively, the “Prior Prospectuses”). This Amendment should be read in conjunction with the Prior Prospectuses, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectuses. This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectuses, and any future amendments or supplements thereto.
We filed the Prior Prospectuses to register the offer and sale of our common stock, par value $0.0001 per share, from time to time pursuant to the terms of that certain At The Market Offering Agreement dated November 8, 2024, or the sales agreement, between H.C. Wainwright & Co., LLC, or Wainwright, acting as the agent, and us (the “At The Market Offering Agreement”).
Since our entry into the At The Market Offering Agreement, we have offered and sold an aggregate of 3,919,559 shares of common stock for gross proceeds of approximately $5.5 million pursuant to the At The Market Offering Agreement.
We are filing this Amendment to supplement the Prior Prospectuses to increase the aggregate amount we intend to sell pursuant to the At The Market Offering Agreement. As of the date of this Amendment, we are offering up to an additional $4,821,200 of our common stock for sale under the At The Market Offering Agreement, not including the shares of common stock previously sold pursuant to the At The Market Offering Agreement.
As of the date of this Amendment, the aggregate market value of our common stock held by non-affiliates of our public float was approximately $30,968,682 based on a total number of 15,514,312 shares of common stock outstanding, of which 14,960,716 shares of common stock were held by non-affiliates, at a price of $2.07 per share, the closing sales price of our common stock on September 23, 2025, which is the highest closing price of our common stock on The Nasdaq Capital Market within the prior 60 days. We have sold approximately $5,501,693 of securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12-calendar month period that ends on and includes the date of this prospectus supplement (excluding this offering). Accordingly, based on the foregoing, we are currently eligible under General Instruction I.B.6 of Form S-3 to offer and sell shares of our Common Stock having an aggregate offering price of up to approximately $4,821,200. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding one-third of our public float in any 12-month period so long as our public float remains below $75.0 million.
Our common stock is listed on The Nasdaq Capital Market under the symbol “HOTH.” On November 12, 2025, the last reported sale price of our common stock was $1.28 per share.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
H.C. Wainwright & Co.
The date of this prospectus supplement is November 13, 2025